Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,680,000 shares, a decline of 14.9% from the November 30th total of 3,150,000 shares. Based on an average trading volume of 329,100 shares, the short-interest ratio is presently 8.1 days. Currently, 5.6% of the shares of the company are sold short.

Analyst Ratings Changes

A number of analysts have commented on the company. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.60.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in Astria Therapeutics by 101.7% in the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 19,735 shares in the last quarter. Barclays PLC lifted its position in Astria Therapeutics by 70.5% during the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 38,321 shares in the last quarter. Wellington Management Group LLP grew its holdings in Astria Therapeutics by 8.7% during the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after acquiring an additional 11,763 shares during the last quarter. RA Capital Management L.P. increased its position in Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares in the last quarter. Finally, Redmile Group LLC bought a new position in shares of Astria Therapeutics in the third quarter worth about $3,423,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Trading Down 0.3 %

Shares of Astria Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, reaching $8.85. 69,863 shares of the stock were exchanged, compared to its average volume of 583,023. Astria Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $16.90. The company has a market cap of $499.44 million, a price-to-earnings ratio of -4.23 and a beta of 0.67. The firm has a 50-day simple moving average of $10.40 and a 200 day simple moving average of $10.73.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.